Intensity Therapeutics Stock (INTS) Skyrockets 195% in Single Trading Session

Biotech investor portfolios just got a massive adrenaline shot as Intensity Therapeutics shares nearly triple in value overnight.

The Unprecedented Surge

INTS stock exploded with a staggering 195% gain that left Wall Street analysts scrambling for explanations. The biotech sector witnessed one of its most dramatic single-day moves this year, turning cautious investors into overnight winners.

Market Mechanics Unleashed

Trading volumes hit unprecedented levels as the stock defied conventional valuation metrics. The surge represents one of those rare moments where clinical-stage biotech potential meets market frenzy—creating the perfect storm for triple-digit returns.

While biotech stocks continue their volatile dance between breakthrough announcements and regulatory hurdles, today's action proves that when these plays work, they really work. Just don't ask about tomorrow's price action—Wall Street's crystal ball remains firmly in the shop for repairs.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The big news from this clinical trial was that INT230-6 achieved a disease control rate of 75% and a median overall survival of 11.9 months. Additionally, the drug treated more than 40% of patients’ total tumor burden. Adding to that, 20% of patients in the less-than-40% group saw their tumors shrink. There were also no dose-limiting toxicities among 64 monotherapy patients, and only seven patients experienced a grade 3 adverse event.

Intensity Therapeutics founder, President, and CEO Lewis Bender stated, “Given the drug’s mechanism of action and the data reported in this paper from over 20 types of metastatic solid cancers, such as breast, sarcoma, pancreatic, lung, and head and neck, we believe the study results show the potential of INT230-6 to achieve clinical benefit for metastatic patients of multiple cancer types with or without the use of radiation, systemic drugs or immunotherapy. As a result, we have initiated randomized controlled studies, including a Phase 3 study in sarcoma.”

Intensity Therapeutics Stock Movement Today

Intensity Therapeutics stock was up 193.74% in pre-market trading on Thursday, following a 5.95% rally yesterday. The shares were down 84.84% year-to-date and 91.79% over the past 12 months.

Today’s clinical trial news spurred heavy trading of INTS stock. With that came some 279 million shares traded, compared to a three-month daily average of about 5.11 million units.

Is Intensity Therapeutics Stock a Buy, Sell, or Hold?

Turning to Wall Street, the analysts’ consensus rating for Intensity Therapeutics is Moderate Buy, based on two Buy ratings over the past three months. With that comes an average INTS stock price target of $2.25, representing a potential 743.01% upside for the shares.